Ruth Marcelyna Ndoen, '- (2021) Studi Penggunaan Lopinavir/Ritonavir Pada Pasien Covid-19 Derajat Berat Dengan Komorbid Hipertensi Dan Diabetes Melitus Di Rumah Sakit Bhayangkara H.S. Samsoeri Mertojoso Surabaya. Skripsi thesis, Universitas Airlangga.

	Text (HALAMAN DEPAN) 1. JUDUL.pdf Download (863kB)
	Text (ABSTRAK) 2. ABSTRACT.pdf Download (129kB)
	Text (DAFTAR ISI) 3. DAFTAR ISI.pdf Download (236kB)
	Text (BAB I PENDAHULUAN) 4. BAB I PENDAHULUAN.pdf Download (144kB)
	Text (BAB II TINJAUAN PUSTAKA) 5. BAB II TINJAUAN PUSTAKA.pdf Restricted to Registered users only Download (412kB) | Request a copy
	Text (BAB III KERANGKA KONSEPTUAL) 6. BAB III KERANGKA KONSEPTUAL.pdf Restricted to Registered users only Download (143kB) | Request a copy
	Text (BAB IV METODE PENELITIAN) 7. BAB IV METODE PENELITIAN.pdf Restricted to Registered users only Download (164kB) | Request a copy
	Text (BAB V HASIL DAN PENELITIAN) 8. BAB V HASIL PENELITIAN DAN PEMBAHASAN.pdf Restricted to Registered users only Download (222kB) | Request a copy
	Text (BAB VI KESIMPULAN) 9. BAB VI KESIMPULAN DAN SARAN.pdf Restricted to Registered users only Download (320kB) | Request a copy
	Text (DAFTAR PUSTAKA) 10. DAFTAR PUSTAKA.pdf Download (280kB)
	Text (LAMPIRAN) 11 LAMPIRAN.pdf Restricted to Registered users only Download (437kB) | Request a copy
	Text (KESEDIAAN PUBLIKASI) KESEDIAAN PUBLIKASI.pdf Restricted to Registered users only Download (331kB) | Request a copy

Abstract

Coronavirus disease 2019 (COVID-19) is a respiratory disease caused by Severe Acute Respiratory Syndrome Coronavirus-2. The aim of this study is to determine the effectiveness by RT-PCR, oxygenation saturation, chest X-ray; and evaluate the side effects of using Lopinavir/Ritonavir (2 x 400/100 mg) PO in severe COVID-19 patients with comorbid hypertension and diabetes mellitus. The data for this observational study were obtained retrospectively from June to December 2020. The total sample that meet the inclusion criteria was 21. Based on the results of the study, it was found that the administration of Lopinavir/Ritonavir (2 x 400/100 mg) PO gave effectiveness in the therapy group A, B, C, and D to the negative RT-PCR results, respectively 10%, 48%, 5%, and 14%; normal oxygen saturation with breathing apparatus 10%, 33%, 5%, and 5%, respectively; and chest X-ray improvement 10%, 29%, 5%, and 14%, respectively. The side effects of Lopinavir/Ritonavir found were an increase in SGOT (46%), SGPT (27%), as well as a QT interval prolongation (5%). It can be concluded that the administartion of Lopinavir/Ritonavir is effective in terms of negative RT-PCR results, improvement of chest X-ray, and oxygen saturation. Monitoring side effects is needed in order to avoid the several potential side effects caused by the therapy.

Actions (login required)

View Item